HONG KONG – Two Chinese biopharma firms, Shanghai Junshi Biosciences Co. Ltd. and Hong Kong-listed CSPC Pharmaceutical Group Ltd. will join hands in developing a combination therapy for breast cancer. Under the agreement, Junshi will provide its PD-1 antibody candidate, JS-001, to be used in combination with CSPC's newly approved paclitaxel for injection (albumin-bound). The two companies will jointly develop, register and commercialize the therapy in greater China.